ReViral

ReViral is a developer of antiviral drugs, aiming to help patients and expand the antiviral market by developing novel first-class compounds. The company's antiviral drug is a fusion inhibitor for RSV, which is a highly effective new small molecule being developed to treat RSV in severe patients, including newborns, allowing for the treatment of patients infected with respiratory syncytial virus (RSV) through the development of novel compounds.